Jinhua Wang,Tatiana Erazo,Fleur M Ferguson,Dennis L Buckley,Nestor Gomez,Pau Muñoz-Guardiola,Nora Diéguez-Martínez,Xianming Deng,Mingfeng Hao,Walter Massefski,Oleg Fedorov,Nana Kwaku Offei-Addo,Paul M Park,Lingling Dai,Amy DiBona,Kelly Becht,Nam Doo Kim,Michael R McKeown,Justin M Roberts,Jinwei Zhang,Taebo Sim,Dario R Alessi,James E Bradner,Jose M Lizcano,Stephen C Blacklow,Jun Qi,Xiang Xu,Nathanael S Gray

Abstract:Bromodomains have been pursued intensively over the past several years as emerging targets for the devel-opment of anti-cancer and anti-inflammatory agents. It has recently been shown that some kinase inhibitors are able to potently inhibit the bromodomains of BRD4. The clinical activities of PLK inhibitor BI-2536 and JAK2-FLT3 inhibitor TG101348 have been attributed to this unexpected poly-pharmacology, indicating that dual-kinase/bromodomain activity may be advantageous in a therapeutic context. However, for target validation and biological investigation, a more selec-tive target profile is desired. Here we report that benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones, versatile ATP-site di-rected kinase pharmacophores utilized in the development of inhibitors of multiple kinases including a number of previ-ously reported kinase chemical probes, are also capable of exhibiting potent BRD4-dependent pharmacology. Using a dual kinase-bromodomain inhibitor of the kinase domains of ERK5 and LRRK2, and the bromodomain of BRD4 as a case study, we define the structure-activity relationships required to achieve dual kinase/BRD4 activity as well as how to di-rect selectivity towards inhibition of either ERK5 or BRD4. This effort resulted in identification of one of the first report-ed kinase-selective chemical probes for ERK5 (JWG-071), a BET selective inhibitor with 1 μM BRD4 IC50 (JWG-115), and additional inhibitors with rationally designed polypharmacology (JWG-047, JWG-069). Co-crystallography of seven representative inhibitors with the first bromodomain of BRD4 demonstrate that distinct atropisomeric conformers rec-ognize the kinase ATP-site and the BRD4 acetyl lysine binding site, conformational preferences supported by rigid dock-ing studies.

Identification of novel Bromodomain inhibitors of Bromodomain Factor 2 ( BDF2) using a fluorescence polarization-base high-throughput assay

Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 (TcBDF2) using a fluorescence polarization-based high-throughput assay

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

A Chemical Toolbox for the Study of Bromodomains and Epigenetic Signaling

Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation

Discovery of High-Affinity Inhibitors of the BPTF Bromodomain

Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign

Discovery of Pyrrolo[3,2-d]pyrimidin-4-one Derivatives As a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.

3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands

Discovery Of 3,5-Dimethylisoxazole Derivatives As Novel, Potent Inhibitors For Bromodomain And Extraterminal Domain (Bet) Family

Discovery of new small molecule inhibitors of the BPTF bromodomain

Discovery of Selective BPTF Bromodomain Inhibitors by Screening and Structure-Based Optimization.

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

Selective inhibition of BET bromodomains

Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains.

Discovery of the Natural Product 3',4',7,8-Tetrahydroxyflavone As a Novel and Potent Selective BRD4 Bromodomain 2 Inhibitor.

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases